Longying Jiang

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Transcription Factor

Epithelial Mesenchymal Transition

Top Venues

Communications chemistry

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Hudie Wei, Haolan Wang, Genxin Wang, Lingzhi Qu, Longying Jiang, Shuyan Dai, Xiaojuan Chen, Ye Zhang, Zhuchu Chen, Youjun Li, Ming Guo, Yongheng Chen
Structures of p53/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity. Nature communications 14 (1) (2023)
Qianmeng Lin, Xiaojuan Chen, Lingzhi Qu, Ming Guo, Hudie Wei, Shuyan Dai, Longying Jiang, Yongheng Chen
Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants. Communications chemistry 5 (1) (2022)
Qianmeng Lin, Xiaojuan Chen, Lingzhi Qu, Ming Guo, Hudie Wei, Shuyan Dai, Longying Jiang, Yongheng Chen
Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants. Communications chemistry 5 (1) (2022)
Shuyan Dai, Lingzhi Qu, Jun Li, Ye Zhang, Longying Jiang, Hudie Wei, Ming Guo, Xiaojuan Chen, Yongheng Chen
Structural insight into the ligand binding mechanism of aryl hydrocarbon receptor. Nature communications 13 (1) (2022)
Xiaojuan Chen, Huiliang Li, Qianmeng Lin, Shuyan Dai, Sitong Yue, Lingzhi Qu, Maoyu Li, Ming Guo, Hudie Wei, Jun Li, Longying Jiang, Guangyu Xu, Yongheng Chen
Structure-based design of a dual-warhead covalent inhibitor of FGFR4. Communications chemistry 5 (1) (2022)
Xiaojuan Chen, Huiliang Li, Qianmeng Lin, Shuyan Dai, Sitong Yue, Lingzhi Qu, Maoyu Li, Ming Guo, Hudie Wei, Jun Li, Longying Jiang, Guangyu Xu, Yongheng Chen
Structure-based design of a dual-warhead covalent inhibitor of FGFR4. Communications chemistry 5 (1) (2022)